Oxaliplatin and 5-FU with Radiotherapy for Rectal Cancer
Author Information
Author(s): Loi S, Ngan S Y K, Hicks R J, Mukesh B, Mitchell P, Michael M, Zalcberg J, Leong T, Lim-Joon D, Mackay J, Rischin D
Primary Institution: Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Hypothesis
Can oxaliplatin combined with infusional 5-fluorouracil and radiotherapy improve treatment outcomes in inoperable and metastatic rectal cancer?
Conclusion
The combination of oxaliplatin with infusional 5-FU and radiotherapy is feasible and well tolerated in patients with inoperable and metastatic rectal cancer.
Supporting Evidence
- Oxaliplatin was well tolerated with manageable side effects.
- 11 out of 12 primary tumors showed metabolic responses on FDG-PET imaging.
- The recommended dose of oxaliplatin was determined to be 85 mg/m2.
Takeaway
This study tested a new treatment for patients with hard-to-treat rectal cancer, and it showed that the treatment is safe and can help patients feel better.
Methodology
A phase I dose escalation study was conducted to determine the recommended dose of oxaliplatin combined with 5-FU and radiotherapy in patients with inoperable or metastatic rectal cancer.
Limitations
The study had a small sample size and was limited to a phase I trial, which primarily focused on safety rather than efficacy.
Participant Demographics
12 males and 4 females, median age 65 years, with 94% having metastatic disease.
Statistical Information
Confidence Interval
95% CI for overall survival was 8 to >18 months.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website